MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Edwards Lifesciences Corporation Net Debt 2011-2026 | EW
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Edwards Lifesciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.32 B | -2.42 B | -528 M | -151 M | -242 M | -561 M | -247 M | 122 M | 218 M | 233 M | 388 M | 729 M | 689 M | 88.9 M | 258 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 729 M | -2.42 B | -249 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
-925 M | $ 186.31 | -0.12 % | $ 14 B |  USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Bruker Corporation
BRKR
|
1.91 B | $ 39.32 | -0.41 % | $ 5.86 K | USA |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
AdaptHealth Corp.
AHCO
|
1.64 B | $ 12.39 | -2.09 % | $ 1.67 B | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Cytosorbents Corporation
CTSO
|
11 M | $ 0.61 | 3.18 % | $ 38 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.61 | 2.56 % | $ 135 M |  France |
 |
Boston Scientific Corporation
BSX
|
9.26 B | $ 63.98 | -0.96 % | $ 94.7 B | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | USA |
 |
ClearPoint Neuro
CLPT
|
3.85 M | $ 10.62 | 1.48 % | $ 301 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Electromed
ELMD
|
-10.5 M | $ 25.38 | -1.28 % | $ 215 M | USA |
 |
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | USA |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
LENSAR
LNSR
|
-10.2 M | $ 6.0 | -4.0 % | $ 71.7 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 17.05 | -4.48 % | $ 400 M | USA |
 |
Globus Medical
GMED
|
-511 M | $ 93.51 | -1.08 % | $ 12.6 B | USA |
 |
Helius Medical Technologies
HSDT
|
-5.12 M | $ 1.96 | 1.04 % | $ 1.19 M | USA |
 |
Butterfly Network
BFLY
|
-65.9 M | $ 5.4 | 11.0 % | $ 1.14 B | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
Inogen
INGN
|
-86.3 M | $ 6.32 | 1.85 % | $ 168 M | USA |
 |
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.03 | -0.48 % | $ 17.4 M | USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
-42.5 M | $ 10.89 | -0.91 % | $ 390 M | USA |
 |
Inspire Medical Systems
INSP
|
-433 M | $ 57.22 | 0.99 % | $ 1.68 B | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 38.45 | -2.56 % | $ 1.19 B | USA |
 |
LivaNova PLC
LIVN
|
-282 M | $ 64.86 | -0.43 % | $ 3.54 B |  Britain |
 |
Integer Holdings Corporation
ITGR
|
1.18 B | $ 88.69 | 1.0 % | $ 3.08 B | USA |
 |
FONAR Corporation
FONR
|
-42.8 M | $ 18.75 | -0.11 % | $ 123 M | USA |
 |
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | USA |
 |
Vivos Therapeutics
VVOS
|
-888 K | $ 1.13 | -23.12 % | $ 11.6 M | USA |
 |
Penumbra
PEN
|
-152 M | $ 332.05 | -0.11 % | $ 12.9 B | USA |